Eintrag weiter verarbeiten
Synergistic enhancement of TRAIL- and tumor necrosis factor α–induced cell death by a phenoxazine derivative
Gespeichert in:
Zeitschriftentitel: | Molecular Cancer Therapeutics |
---|---|
Personen und Körperschaften: | , , , , , , , , , |
In: | Molecular Cancer Therapeutics, 4, 2005, 7, S. 1121-1127 |
Format: | E-Article |
Sprache: | Englisch |
veröffentlicht: |
American Association for Cancer Research (AACR)
|
Schlagwörter: |
Zusammenfassung: | <jats:title>Abstract</jats:title> <jats:p>2-Amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one (Phx-1) has been developed as a novel phenoxazine derivative having an anticancer activity on a variety of cancer cell lines as well as transplanted tumors in mice with minimal toxicity to normal cells. We examined the effects of Phx-1 on Jurkat cells, a human T cell line. Phx-1 inhibited proliferation of the cells in a dose-dependent manner but hardly induced cell death, suggesting that Phx-1 acts primarily as an antiproliferative reagent but not as a cytocidal drug. Phx-1 enhanced tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-induced apoptotic cell death about 100-fold. Tumor necrosis factor α, which alone does not induce cell death of Jurkat cells, caused apoptosis in combination with Phx-1. These enhancements of cell death were not due to up-regulation of the death receptors. Phx-1 decreased serum-induced phosphorylation of Akt, a kinase involved in cell proliferation and survival, and inhibited complex III of mitochondrial respiratory chain. Considering that both TRAIL and Phx-1 have only marginal cytotoxicity to most normal cells, Phx-1 may provide an ideal combination for cancer therapy with TRAIL.</jats:p> |
---|---|
Umfang: | 1121-1127 |
ISSN: |
1535-7163
1538-8514 |
DOI: | 10.1158/1535-7163.mct-05-0067 |